FPH upgrades earnings guidance driven by currency rate movements
Good news and bad news on Friday from NZ-based Fisher and Paykel Healthcare.
Read More
At Fisher & Paykel Healthcare, we fully understand the life-changing impact that can result from delivering inspired and world-leading healthcare solutions.
After all, we changed the way the world delivers respiratory humidification to critically ill patients in hospital, and were the first organisation in the world to make a humidifier specifically for use in the treatment of patients with obstructive sleep apnea.
Today, through an unrivalled commitment to innovation; to doing the right thing; and doing what is best for the patient, we continue to inspire world-leading healthcare solutions.
Our team of self-motivated, empathetic and committed individuals is our strength. It is this team; our originality; the value we place on relationships; our international perspective; and the utmost care for all patients, customers, suppliers, shareholders, as well as the environment, that will ultimately ensure we will be the healthcare company of choice.
Good news and bad news on Friday from NZ-based Fisher and Paykel Healthcare.
Read More
New Zealand-based Fisher & Paykel Healthcare Corporation has increased its interim dividend from 17.5 NZ cents to 18 NZ cents for the six months ending September 30, following a robust performance with a 16% rise in revenue and a 12% increase in after-tax earnings.
Read More
Fisher & Paykel Healthcare Corporation looks on track to make guidance for the six months to September and the full financial year ending March 2024.
Read More
Let's start the new week with a couple quick stories we couldn't fit into our bumper weekend edition, involving Fisher & Paykel Healthcare and Ausgold.
Read More
Shares in Fisher and Paykel Healthcare leapt 14% yesterday after the company produced a forecast for a second half improvement on what was a solid first six-months.
Read More
Buy rating retained. Target price falls to NZ$24 from NZ$25.75.
Read More
The Outperform rating is retained and the target price decreases to NZ$29.87 from NZ$37.57.
Read More
The Neutral rating is retained and the target price decreases to $27.00 from $34.00.
Read More
The stock is still considered expensive and a Neutral rating is maintained. Target is raised to NZ$32.30 from NZ$31.84.
Read More
UBS retains a Sell rating, believing the stock is overvalued and there will be negative earnings momentum as covid-19 hospitalisation rates fade. Target is NZ$22.65.
Read More